Submitted: 09 May 2017
Accepted: 01 Sep 2017
First published online: 06 Sep 2017
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

J Renal Inj Prev. 2018;7(3):148-151.
doi: 10.15171/jrip.2018.37

Scopus id: 85050166124
  Abstract View: 237
  PDF Download: 238


Renal function in β-thalassemia major receiving desferal versus deferasirox

Foroogh Sabzghabaei 1, Maryam Darnahal 1 * , Azita Azarkeivan

1 Department of Internal Medicine, Iran University of Medical Science, Tehran, Iran
2 Department of Thalassemia Clinic, Transfusion Research Center, Institute for Research and Education in Transfusion Medicine, Tehran, Iran
*Corresponding author: Maryam Darnahal, Email:


Introduction: Deferasirox is a new oral iron chelating agent which has been administered in β-thalassemia major patients in last few years. There is some reports regarding nephrotoxicity of this agent; however, no comparative study has been conducted yet.

Objectives: The aim of this study was to compare the prevalence of kidney dysfunction in β-thalassemia major patients receiving either desferal or deferasirox as iron chelating agents.

Patients and Methods: In this cross-sectional study, adult patients with β-thalassemia major who received 25 mg/kg/d of desferal or 25 mg/kg/d of deferasirox were studied. We compared them for serum calcium (Ca), creatinine (Cr) levels and 24 hours urine collection for proportion of Ca and protein. Estimated glomerular filtration rate (eGFR) was calculated by Cockcroft-Gault formula.

Results: Twenty-seven patients receiving desferal and 23 patients receiving deferasirox were evaluated. There was no significant difference of calciuria (P=0.19), glycosuria (P=0.508), mean 24-hour urine proteinuria (P=0.44), mean serum Cr (P=0.47), serum Ca level (P = 0.067) and mean eGFR (P=0.42) between two groups.

Conclusion: There is no significant difference of hypercalciuria, glycosuria, mean eGFR, proteinuria, and also serum Cr between β-thalassemia major patients who received desferal or deferasirox.

Implication for health policy/practice/research/medical education:

In a study on 50 β-thalassemia major patients (27 individuals receiving desferal and 23 with deferasirox) no significant difference of renal function, hypercalciuria, glycosuria and proteinuria between two groups was detected.

Please cite this paper as: Sabzghabaei F, Darnahal M, Azarkeivan A. Renal function in β-thalassemia major receiving desferal versus deferasirox. J Renal Inj Prev. 2018;7(3):148-151. doi: 10.15171/jrip.2018.37.

First name
Last name
Email address
Security code

Article Viewed: 237

Your browser does not support the canvas element.

PDF Downloaded: 238

Your browser does not support the canvas element.